TGFB1 and neoplasm: It was shown that elevated TGFβ1 plasma levels and upregulated downstream gene targets, such as TWIST1 and SNAI2, correlated with poor patient prognosis23,24, while it was also reported that reduced TGFβRII immunostaining in LUSC patients is associated with a more aggressive tumor behavior and reduced patient survival25.